On 5 February 2021, Teva Pharmaceutical Industries and Cephalon brought an action before the CJEU against the European Commission to appeal the fine they received. The European Commission fined the pharmaceuticals on 26 November 2020 for establishing in a patent dispute settlement agreement that Cephalon would not enter the market with a general version of the sleeping disorder medicine modafinil. According to the Commission, this was a forbidden pay-for-delay agreement, a restriction of competition by object. The pharmaceutical companies seek annulment or reduction of the imposed fine.
 Published in the Official Journal on 22 March 2021, OJ 22 March 2021, C 98/34. Case number T-74/21.